文献速递乳腺MR

乳腺癌新辅助化疗早期疗效的DWI自动ADC测量

Automated Apparent Diffusion Coefficient Measurement of Breast Tumors in Diffusion-weighted MRI for Early Neoadjuvant Chemotherapy Response Assessment.
PubMed 文献 · Radiol Imaging Cancer · 2026-01-01

本研究回顾性分析ACRIN 6698试验中226例乳腺癌患者数据,通过图像配准将DCE-MRI肿瘤ROI自动转移至DWI,计算基线至治疗早期的ΔADC。自动ADC测量在71例重复检查亚组中可重复性良好,ΔADC可预测病理完全缓解。

要点

  • 自动ROI转移测量的ΔADC可预测乳腺癌新辅助化疗pCR
  • HER2阳性亚组ΔADC预测效能高于HER2阴性亚组
  • 自动ADC测量在重复检查中可重复性良好

核心结论

  • 自动ADC测量方法可重复,肿瘤ΔADC可在治疗早期预测病理完全缓解。
  • HER2阳性亚组的ΔADC预测效能高于HER2阴性亚组。

研究设计与样本

  • 回顾性分析美国放射学会影像网络6698试验数据,时间为2012年8月至2015年1月。
  • 分析队列共226例乳腺癌参与者,平均年龄48岁±10。
  • 通过图像配准将DCE-MRI肿瘤ROI自动转移至DWI以获得自动ADC测量。
  • 以病理完全缓解为参考标准,采用ROC曲线分析ΔADC预测效能。
  • 重复性在71例test-retest亚组中评估。

关键影像表现/征象

  • 自动ROI转移无需人工勾画DWI肿瘤边界,减少操作者依赖性。
  • ΔADC由基线至治疗早期的ADC变化计算获得。

诊断标准与关键数值

  • ΔADC预测pCR的AUC为0.61(95% CI:0.53,0.69;P = .008)。
  • HER2阳性亚组AUC为0.69(95% CI:0.54,0.93)。
  • HER2阴性亚组AUC为0.52(95% CI:0.41,0.62;P = .06)。
  • 自动ADC测量一致性指数为0.82(95% CI:0.77,0.85)。

临床应用与阅片要点

  • 可尝试将DCE-MRI肿瘤ROI经配准自动转移到DWI,减少人工测量ADC的变异性。
  • HER2阳性患者早期ΔADC对pCR的预测价值相对较高。

局限性

  • 研究为回顾性分析。
  • 未来还需进行外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To develop a fully automated method for measuring apparent diffusion coefficient (ADC) for breast tumors in diffusion-weighted MRI that is objective, repeatable, and reproducible for assessing early response to neoadjuvant chemotherapy. Materials and Methods This study was a retrospective analysis of American College of Radiology Imaging Network 6698 trial data (August 2012-January 2015). Regions of interest (ROIs) were automatically derived by transferring the tumor ROI from dynamic contrast-enhanced MRI to diffusion-weighted MRI via image registration, and the ΔADC were calculated from baseline to early treatment. The ΔADC performance was assessed for predicting a pathologic complete response (pCR) using receiver operating characteristic curve analysis. The analysis was performed in all participants and in subgroups defined by tumor human epidermal growth factor receptor 2 (HER2) status. The reproducibility of automated tumor ADC measurements was assessed in a test-retest subcohort. Results The analysis cohort included 226 participants with breast cancer (mean age, 48 years ± 10 [SD]). Automated ADC measurements were reproducible in the test-retest subcohort (n = 71; estimated agreement index, 0.82 [95% CI: 0.77, 0.85]). The ΔADC from the automated ROI predicted pCR, with an area under the receiver operating characteristic curve (AUC) of 0.61 (95% CI: 0.53, 0.69; P = .008). The AUC in the HER2-positive subcohort (0.69 [95% CI: 0.54, 0.93]) was higher than that in the HER2-negative subcohort (0.52 [95% CI: 0.41, 0.62]; P = .06). Conclusion The automated ADC measurement method was reproducible, and tumor ΔADC could predict pCR early. External validation will be included in future work. Keywords: Breast, MRI, DWI, Diffusion-weighted Imaging, Tumor Response, DCE, Dynamic Contrast-enhanced, MR Imaging, MR-Diffusion-weighted Imaging, MR-Dynamic Contrast-enhanced Clinical trial registration no. NCT01564368

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Le, Li, Wilmes, et al. Automated Apparent Diffusion Coefficient Measurement of Breast Tumors in Diffusion-weighted MRI for Early Neoadjuvant Chemotherapy Response Assessment. Radiol Imaging Cancer. 2026. PMID: 42496228. doi:10.1148/rycan.250606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。